The testosterone patch for women.
Has the FDA discriminated against female sexual dysfunction by not endorsing Procter & Gamble's (P&G) Intrinsa? Has the pendulum swung so far to the right that drugs for sexual medicine receive undue scrutiny? Why is testosterone replacement therapy available for men, but not for women? How should the pharmaceutical industry proceed with future studies? How should clinicians guide their patients? In this third and final perspective regarding Intrinsa, Sheryl Kingsberg, PhD, an expert on female sexual dysfunction and one of the lead investigators of the Intrinsa clinical trials, addresses these questions. This is a highly charged issue that appears to be on the agenda for the foreseeable future.
Kingsberg
S A
SA
Reproductive Biology & Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. sheryl.kingsberg@uhhs.com
D005260:Female; D006801:Humans; D008297:Male; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D016387:Women's Health
C503596:Intrinsa; D013739:Testosterone